Lord, Abbett & Co. LLC Moon Lake Immunotherapeutics Transaction History

Lord, Abbett & Co. LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Oct 07, 2024	SELL	$43.78 - $63.86 $3.19 Million - $4.65 Million	-72,832 Reduced 45.71%	86,487 $4.34 Million
Q1 2024 May 09, 2024	SELL	$43.78 - $63.86 $3.19 Million - $4.65 Million	-72,832 Reduced 45.71%	86,487 $4.34 Million
Q4 2023 Oct 07, 2024	SELL	$36.35 - $63.02 $607,699 - $1.05 Million	-16,718 Reduced 9.5%	159,319 $9.62 Million
Q4 2023 Feb 12, 2024	SELL	$36.35 - $63.02 $607,699 - $1.05 Million	-16,718 Reduced 9.5%	159,319 $9.62 Million
Q3 2023 Oct 07, 2024	SELL	$48.35 - $61.26 $902,501 - $1.14 Million	-18,666 Reduced 9.59%	176,037 $10 Million
Q3 2023 Nov 13, 2023	SELL	$48.35 - $61.26 $902,501 - $1.14 Million	-18,666 Reduced 9.59%	176,037 $10 Million
Q2 2023 Oct 07, 2024	BUY	$19.01 - $51.79 $3.7 Million - $10.1 Million	194,703 New	194,703 $9.93 Million
Q2 2023 Aug 14, 2023	BUY	$19.01 - $51.79 $3.7 Million - $10.1 Million	194,703 New	194,703 $9.93 Million

124

58.2M

52.2K

38K

Ticker MLTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,925,600
Market Cap $1.92B
Description
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or rad...

Get notified when there are updates to the investment portfolio of Lord, Abbett & Co. LLC, based on Form 13F filings with the SEC.

Stay updated on Lord, Abbett & Co. LLC with notifications on news.